Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celladon brings in $43mm through its Series D venture round; adds $10mm

Executive Summary

Celladon Corp. has raised $43mm through what appears to be its Series D venture round. Pfizer Venture Investments led and was joined by fellow new investors Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners, and all returning shareholders, including JEnterprise Partners Venture Capital, Johnson & Johnson Development Corp., and Venrock Associates. Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Capital Management, and GBS Venture Partners will each add one member to Celladon's board. The company is developing Phase II Mydicar for advanced heart failure with Targeted Genetics under a 2005 deal.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies